Bank of Montreal’s BioMarin Pharmaceuticals BMRN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$3.75M Buy
65,500
+1,747
+3% +$95.7K ﹤0.01% 1478
2026
Q1
$3.6M Sell
63,753
-4,825
-7% -$281K ﹤0.01% 1439
2025
Q4
$4.08M Sell
68,578
-10,449
-13% -$569K ﹤0.01% 1403
2025
Q3
$4.28M Buy
79,027
+5,207
+7% +$298K ﹤0.01% 1361
2025
Q2
$4.06M Buy
73,820
+2,271
+3% +$134K ﹤0.01% 1334
2025
Q1
$5.06M Buy
71,549
+3,397
+5% +$229K ﹤0.01% 1165
2024
Q4
$4.48M Sell
68,152
-14,519
-18% -$973K ﹤0.01% 1254
2024
Q3
$5.83M Sell
82,671
-168,254
-67% -$14.1M ﹤0.01% 1250
2024
Q2
$21.4M Buy
250,925
+181,935
+264% +$15.1M 0.01% 743
2024
Q1
$6.03M Buy
68,990
+559
+0.8% +$50K ﹤0.01% 1147
2023
Q4
$6.7M Sell
68,431
-224,356
-77% -$19.8M ﹤0.01% 1166
2023
Q3
$26.5M Buy
292,787
+220,464
+305% +$19.6M 0.01% 622
2023
Q2
$6.99M Sell
72,323
-43,507
-38% -$4.09M ﹤0.01% 1178
2023
Q1
$11.3M Buy
115,830
+556
+0.5% +$57.6K ﹤0.01% 895
2022
Q4
$12.1M Buy
115,274
+38,582
+50% +$3.62M 0.01% 899
2022
Q3
$6.6K Sell
76,692
-181,686
-70% -$16.2M ﹤0.01% 1202
2022
Q2
$22.1K Buy
258,378
+27,454
+12% +$2.19M 0.01% 720
2022
Q1
$18.3M Buy
230,924
+75,322
+48% +$6.3M 0.01% 862
2021
Q4
$13.9M Buy
155,602
+11,755
+8% +$970K 0.01% 859
2021
Q3
$11.1M Buy
143,847
+9,632
+7% +$760K 0.01% 1229
2021
Q2
$11.2M Sell
134,215
-2,939
-2% -$233K 0.01% 1204
2021
Q1
$10.7M Buy
137,154
+36,883
+37% +$3.01M 0.01% 975
2020
Q4
$8.15M Sell
100,271
-10,029
-9% -$795K 0.01% 1131
2020
Q3
$8.33M Buy
110,300
+14,683
+15% +$1.49M 0.01% 935
2020
Q2
$12.1M Buy
95,617
+15,004
+19% +$1.49M 0.01% 755
2020
Q1
$6.94M Sell
80,613
-14,817
-16% -$1.28M 0.01% 848
2019
Q4
$8.07M Sell
95,430
-43,978
-32% -$3.32M 0.01% 1100
2019
Q3
$9.4M Buy
139,408
+54,828
+65% +$4.22M 0.01% 897
2019
Q2
$7.25M Sell
84,580
-20,434
-19% -$1.75M 0.01% 1040
2019
Q1
$9.33M Sell
105,014
-4,343
-4% -$403K 0.01% 882
2018
Q4
$9.31M Sell
109,357
-710
-0.6% -$67.5K 0.01% 808
2018
Q3
$10.7M Sell
110,067
-4,686
-4% -$468K 0.01% 873
2018
Q2
$10.8M Buy
114,753
+1,150
+1% +$101K 0.01% 859
2018
Q1
$9.21M Buy
113,603
+4,469
+4% +$384K 0.01% 886
2017
Q4
$9.73M Buy
109,134
+6,802
+7% +$591K 0.01% 866
2017
Q3
$9.52M Buy
102,332
+7,749
+8% +$685K 0.01% 875
2017
Q2
$8.59M Sell
94,583
-49,330
-34% -$4.49M 0.01% 911
2017
Q1
$12.6M Buy
143,913
+56,388
+64% +$5.02M 0.01% 724
2016
Q4
$7.49M Sell
87,525
-2,778
-3% -$239K 0.01% 910
2016
Q3
$8.36M Sell
90,303
-3,987
-4% -$375K 0.01% 897
2016
Q2
$7.34M Sell
94,290
-196
-0.2% -$16.7K 0.01% 946
2016
Q1
$7.79M Buy
94,486
+13,396
+17% +$1.09M 0.01% 838
2015
Q4
$8.49M Buy
81,090
+7,448
+10% +$778K 0.01% 788
2015
Q3
$7.76M Sell
73,642
-166,069
-69% -$22.2M 0.01% 812
2015
Q2
$32.8M Buy
239,711
+197,858
+473% +$24.5M 0.04% 378
2015
Q1
$5.22M Sell
41,853
-4,175
-9% -$442K 0.01% 1030
2014
Q4
$4.16M Buy
46,028
+1,397
+3% +$116K ﹤0.01% 1098
2014
Q3
$3.22M Buy
44,631
+13,356
+43% +$878K ﹤0.01% 1261
2014
Q2
$1.95M Buy
31,275
+3,951
+14% +$239K ﹤0.01% 1464
2014
Q1
$1.86M Buy
27,324
+1,948
+8% +$144K ﹤0.01% 1363
2013
Q4
$1.78M Buy
25,376
+471
+2% +$32K ﹤0.01% 1229
2013
Q3
$1.8M Sell
24,905
-804
-3% -$53.4K ﹤0.01% 1207
2013
Q2
$1.43M Buy
+25,709
New +$1.6M ﹤0.01% 1238

Other funds holding BMRN

Bank of Montreal's BMRN Position: Q2 2026 in Review

Bank of Montreal increased its BioMarin Pharmaceuticals (BMRN) stake by 2.7% in Q2 2026, buying an estimated $95.7K and bringing the position to 65,500 shares worth $3.75M. The position accounts for ﹤0.01% of the portfolio, ranked #1478.

Bank of Montreal first reported a position in BMRN in Q2 2013 and has held it in 53 quarters since. The position peaked at $32.8M in Q2 2015. 526 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Bank of Montreal held 65,500 shares of BioMarin Pharmaceuticals worth $3.75M as of Q2 2026.
  • Bank of Montreal bought 1,747 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $95.7K.
  • BioMarin Pharmaceuticals made up ﹤0.01% of Bank of Montreal's portfolio in Q2 2026, its #1478 holding.
  • Bank of Montreal first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
  • Bank of Montreal's BioMarin Pharmaceuticals position peaked at $32.8M in Q2 2015.
  • 526 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Bank of Montreal's 13F filing for Q2 2026, filed 12 Aug 2026.